Evidence map›Paper›PMID 39128264›Full record

ArticleBiochemical and biophysical research communications2024

Small molecular weight epigenetic inhibitors modulate the extracellular matrix during pancreatic acinar ductal metaplasia.

Corey M Perkins, Yating Mao, Jinmai Jiang, Diana J Wilkie, Bo Han, Qi-Yin Chen, Hendrik Luesch, Jamel Ali, Thomas D Schmittgen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical and biophysical research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Corey M PerkinsDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA; Florida-California Cancer Research Education and Engagement (CaRE (2)) Health Equity Center, USA.
Yating MaoDepartment of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Tallahassee, FL, USA; National High Magnetic Field Laboratory, Tallahassee, FL, USA; Florida-California Cancer Research Education and Engagement (CaRE (2)) Health Equity Center, USA.
Jinmai JiangDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA; Florida-California Cancer Research Education and Engagement (CaRE (2)) Health Equity Center, USA.
Diana J WilkieDepartment of Behavioral Nursing Science, College of Nursing, University of Florida, Gainesville, FL, USA; Florida-California Cancer Research Education and Engagement (CaRE (2)) Health Equity Center, USA.
Bo HanDepartment of Surgery, University of Southern California, Los Angeles, CA, USA; Florida-California Cancer Research Education and Engagement (CaRE (2)) Health Equity Center, USA.
Qi-Yin ChenDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA; Center for Natural Products, Drug Discovery and Development, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Hendrik LueschDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA; Center for Natural Products, Drug Discovery and Development, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Jamel AliDepartment of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Tallahassee, FL, USA; National High Magnetic Field Laboratory, Tallahassee, FL, USA; Florida-California Cancer Research Education and Engagement (CaRE (2)) Health Equity Center, USA. Electronic address: jali@eng.famu.fsu.edu.
Thomas D SchmittgenDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA; Florida-California Cancer Research Education and Engagement (CaRE (2)) Health Equity Center, USA. Electronic address: tschmittgen@ufl.edu.

Funding

Tissue Modeling & Drug Development Shared Resources CoreU54CA233444 · NCI · UNIVERSITY OF FLORIDA · PI Chanita A. Hughes-Halbert, Tianze Jiao · 2018 to 2026
$12.1M
Tissue Modeling CoreU54CA233465 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JOYCE M RICHEY · 2018 to 2026
$11.9M
Tissue Modeling CoreU54CA233396 · NCI · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI Bereket - Mochona · 2018 to 2026
$9.8M
Novel Targeted Anticancer Agents from Marine CyanobacteriaR01CA172310 · NCI · UNIVERSITY OF FLORIDA · PI HENDRIK LUESCH · 2013 to 2026
$5.8M
NCI NIH HHS R01 CA172310NCI NIH HHS U54 CA233396NCI NIH HHS U54 CA233444NCI NIH HHS U54 CA233465
6 · The paper itself

Abstract

The pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment is distinguished by a high degree of fibrosis and inflammation, known as desmoplasia. Desmoplasia increases the stromal deposition and extracellular matrix (ECM) stiffness observed in the tumor microenvironment, contributing to the dampened penetration of pharmacological agents. The molecular and biophysical composition of the ECM during the earliest cellular changes in the development of PDAC, i.e. acinar ductal metaplasia (ADM), has not been extensively explored. We report that the mRNA expression of key protein components of the ECM increases during ADM in p48

Indexed as

Carcinoma, Pancreatic DuctalEpigenesis, GeneticExtracellular MatrixMetaplasiaAcinar CellsAnimalsDepsipeptidesHistone Deacetylase InhibitorsMiceOrganoidsPancreatic DuctsPancreatic NeoplasmsTumor MicroenvironmentDepsipeptidesHistone Deacetylase InhibitorsromidepsinAcinar ductal metaplasiaBiomechanicsMicrorheologyPancreas plasticityPancreatic cancer

Identifiers

PMID39128264
PMCPMC12037226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.